ALL of the following should be available and of interest USA & worldwide:
CLL SOCIETY: THIS WEEK September 13, 2022 (Newsletter)
myemail.constantcontact.com...
SPECIAL FEATURE: Dr. Brian Koffman is a Guest on the Healthcare Unfiltered Podcast
Healthcare Unfiltered is an engaging podcast that tackles subjects across the field of healthcare in the most honest and transparent manner. The host Chadi Nabhan, MD, MBA, is an award-winning hematologist/oncologist with expertise in lymphomas and healthcare policy. In the newest episode released today, CLL Society’s own Dr. Brian Koffman is a guest, alongside Dr. Alan Skarbnik, who is a member of CLL Society's Medical Advisory Board, and Dr. Elizabeth Brem who specializes in lymphomas at UC Irvine. The episode discusses the importance of including patients in the process of planning for treatment in CLL/SLL. Also Dr. Koffman provides the patient’s perspective in the conversation and offers advice for how fellow patients can engage in shared decision-making conversations with their healthcare team.
Listen to the Episode: chadinabhan.com/healthcare-...
-
WHAT'S NEW IN CLL/SLL- ASH 2021:
Patient Awareness, Knowledge, and Preferences of Fixed Duration Therapy and MRD
What do patients and caregivers know about undetectable measurable residual disease (uMRD) testing and finite-duration therapy? Dr. Brian Koffman explains further what was discovered about patient awareness, knowledge, and preferences through CLL Society’s research presented at the annual ASH 2021 meeting.
Read More: cllsociety.org/2022/09/ash-...
-
ASH 2021: Dr. Talha Munir on MRD After Fixed Duration Ibrutinib Plus Venetoclax
Combining ibrutinib and venetoclax as a frontline treatment may help patients reach undetectable measurable residual disease (uMRD) while also limiting the amount of time patients need to spend on treatment. Watch our interview with Dr. Talha Munir to learn more.
Read More: cllsociety.org/2022/09/ash-...
-
ASCO 2022: Four-year Follow-Up from a Phase 2 Study of Obinutuzumab, Ibrutinib, and Venetoclax
Obinutuzumab, ibrutinib, and venetoclax have been proven to provide patients with CLL/SLL a durable remission in both the treatment naïve and relapsed/refractory settings. Learn more about promising outcomes for patients from the four-year follow-up data on this triple combination treatment option.
Read More: cllsociety.org/2022/08/asco...
-
COVID-19 UPDATES
New Bivalent COVID-19 Booster Guidance Released by the CDC
Nearly two and a half years into the COVID-19 pandemic, the FDA and CDC have approved the updated mRNA vaccines from Pfizer and Moderna to include enhanced protection against both the BA.4 and BA.5 variants. Learn about the most recent guidance.
Read More: cllsociety.org/2022/09/new-...
-
UPCOMING EVENTS - Webinar
Playing CLL/SLL Chess: Planning Your Therapy Moves - Wednesday, October 26th at 12 PM PT / 3 PM ET
Treating CLL/SLL is a little like a chess game, as one needs to always be thinking a few moves ahead. Most treatments for CLL/SLL are not curative, and when relapse occurs it is important to have a plan in place with some options that can knock back the disease again. Join CLL/SLL expert Dr. Susan O’Brien, and 20-year CLL survivor Terry Evans, as they explain the CLL/SLL treatment landscape, what is known and unknown, and describe how to better participate in shared decision-making with your healthcare provider.
Register Now: cllsociety.org/playing-cll-...
-
EDUCATION ON-DEMAND
It’s Not Over Yet: The Ongoing Impact of COVID-19 for Those with CLL/SLL
If you missed the COVID-19 webinar with Dr. Shmuel Shoham, you can catch the replay here!
cllsociety.org/2022/08/its-...
Also, check out the Audience Question & Answer document in the resources section.
cllsociety.org/docs/COVID-1...
-
Len
